← Back to patent-cliff list
Galeflaprit
Tier C — Watch / tradeGaleflaprit
Novartis
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Proteasome
Indications (approved)：皮肤利什曼病, Chagas disease, 内脏利什曼病
Regional status
US
Phase II
2025-04-28
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Galeflaprit?
Approved indications include: 皮肤利什曼病, Chagas disease, 内脏利什曼病.
When does the Galeflaprit patent expire?
No public expiry year is available for Galeflaprit yet; this page updates once verified.
How do I get a quote for Galeflaprit intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03